Provided by Tiger Fintech (Singapore) Pte. Ltd.

Foghorn Therapeutics Inc.

4.43
-0.0500-1.12%
Post-market: 4.430.00000.00%17:45 EDT
Volume:44.98K
Turnover:202.20K
Market Cap:246.28M
PE:-2.42
High:4.73
Open:4.57
Low:4.39
Close:4.48
Loading ...

Sector Update: Health Care Stocks Mixed Pre-Bell Monday

MT Newswires Live
·
16 Dec 2024

Foghorn Therapeutics Inc. : Jefferies Cuts Target Price to $14 From $18

THOMSON REUTERS
·
16 Dec 2024

Foghorn Therapeutics price target lowered to $14 from $18 at Jefferies

TIPRANKS
·
16 Dec 2024

Foghorn Therapeutics Discontinues Development of FHD-286 Clinical Program; Shares Fall Pre-Bell

MT Newswires Live
·
16 Dec 2024

BUZZ-Foghorn falls after discontinuing independent development of its cancer treatment

Reuters
·
16 Dec 2024

Foghorn Therapeutics Ends Solo Development of FHD-286

Dow Jones
·
16 Dec 2024

Foghorn Therapeutics Shares Down 37.2% Premarket After Co Halts Independent Development of Cancer Treatment

THOMSON REUTERS
·
16 Dec 2024

BRIEF-Foghorn Therapeutics Provides Update On Fhd-286 Clinical Development Program

Reuters
·
16 Dec 2024

Foghorn Therapeutics Advances Precision Oncology Pipeline

TIPRANKS
·
16 Dec 2024

Foghorn to discontinue independent development of FHD-286 with decitabine in AML

TIPRANKS
·
16 Dec 2024

Foghorn Therapeutics Inc. - to Discontinue Independent Development of Fhd-286 for Aml

THOMSON REUTERS
·
16 Dec 2024

Foghorn Therapeutics Inc. - Phase 1 Trial of Fhd-286 Showed Clinical Responses but Did Not Meet Threshold

THOMSON REUTERS
·
16 Dec 2024

Foghorn Therapeutics Inc. - to Prioritize Proprietary Pipeline and Lilly Collaboration Programs

THOMSON REUTERS
·
16 Dec 2024

Foghorn Therapeutics Inc. - Evaluating Partnerships and Ists to Advance Fhd-286

THOMSON REUTERS
·
16 Dec 2024

Foghorn Therapeutics Provides Update on Fhd-286 Clinical Development Program and Strategic Priorities

THOMSON REUTERS
·
16 Dec 2024

This Foghorn Therapeutics Insider Reduced Their Stake By 13%

Simply Wall St.
·
13 Dec 2024